Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment

Increased risk reported in patients within 18 months of stopping/delaying treatment for osteoporosis. Benefits &risks should be evaluated before initiating treatment, particularly in those with previous vertebral fracture; treatment should not be stopped without specialist review


Medicines and Healthcare products Regulatory Agency